MARKET

MAZE

MAZE

Maze Therapeutics
NASDAQ
15.74
+0.69
+4.58%
After Hours: 16.00 +0.26 +1.65% 19:27 07/14 EDT
OPEN
14.83
PREV CLOSE
15.05
HIGH
15.86
LOW
14.35
VOLUME
71.62K
TURNOVER
--
52 WEEK HIGH
17.00
52 WEEK LOW
6.71
MARKET CAP
674.10M
P/E (TTM)
-11.9906
1D
5D
1M
3M
1Y
5Y
1D
Maze Therapeutics participates in a conference call with JPMorgan
TipRanks · 16h ago
Weekly Report: what happened at MAZE last week (0707-0711)?
Weekly Report · 18h ago
Maze Therapeutics Inc. to Participate in H.C. Wainwright 4th Annual Kidney Virtual Conference
Reuters · 4d ago
Wedbush bullish on Maze Therapeutics, initiates with an Outperform
TipRanks · 6d ago
Maze Therapeutics Price Target Announced at $17.00/Share by Wedbush
Dow Jones · 6d ago
Wedbush Initiates Coverage On Maze Therapeutics with Outperform Rating, Announces Price Target of $17
Benzinga · 6d ago
MAZE THERAPEUTICS INC <MAZE.O>: WEDBUSH INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $17
Reuters · 6d ago
Maze Therapeutics initiated with an Outperform at Wedbush
TipRanks · 6d ago
More
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.

Webull offers Maze Therapeutics, Inc. stock information, including NASDAQ: MAZE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MAZE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MAZE stock methods without spending real money on the virtual paper trading platform.